Trinity Street Asset Management LLP Has $152.42 Million Holdings in Icon Plc $ICLR

Trinity Street Asset Management LLP grew its holdings in shares of Icon Plc (NASDAQ:ICLR) by 3.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 870,973 shares of the medical research company’s stock after buying an additional 29,558 shares during the quarter. Icon accounts for about 10.4% of Trinity Street Asset Management LLP’s investment portfolio, making the stock its 5th biggest position. Trinity Street Asset Management LLP’s holdings in Icon were worth $152,420,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Tributary Capital Management LLC grew its stake in Icon by 84.5% in the third quarter. Tributary Capital Management LLC now owns 11,752 shares of the medical research company’s stock worth $2,057,000 after purchasing an additional 5,381 shares in the last quarter. SeaBridge Investment Advisors LLC bought a new stake in Icon during the 3rd quarter valued at $2,589,000. Artisan Partners Limited Partnership lifted its holdings in shares of Icon by 67.4% in the 2nd quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company’s stock worth $1,045,039,000 after buying an additional 2,893,946 shares during the period. Ninety One UK Ltd grew its position in shares of Icon by 0.4% during the 3rd quarter. Ninety One UK Ltd now owns 3,006,141 shares of the medical research company’s stock worth $526,075,000 after buying an additional 12,489 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in shares of Icon by 11.2% during the second quarter. American Century Companies Inc. now owns 531,395 shares of the medical research company’s stock valued at $77,292,000 after buying an additional 53,458 shares during the period. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

Icon Trading Down 1.2%

NASDAQ ICLR opened at $182.56 on Friday. Icon Plc has a 52 week low of $125.10 and a 52 week high of $211.00. The company has a 50 day moving average price of $178.77 and a 200 day moving average price of $173.75. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The firm has a market cap of $14.74 billion, a PE ratio of 24.70, a price-to-earnings-growth ratio of 3.89 and a beta of 1.26.

Analyst Ratings Changes

ICLR has been the subject of several recent research reports. BMO Capital Markets began coverage on Icon in a report on Thursday, November 13th. They issued a “market perform” rating and a $175.00 price objective for the company. Bank of America lowered shares of Icon from a “buy” rating to a “neutral” rating and set a $195.00 price target for the company. in a report on Monday, December 15th. TD Cowen lowered their price target on shares of Icon from $183.00 to $172.00 and set a “hold” rating for the company in a research report on Friday, October 24th. Mizuho set a $216.00 price objective on shares of Icon in a research note on Friday, January 9th. Finally, UBS Group set a $220.00 price objective on shares of Icon in a research note on Friday, October 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and twelve have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $199.87.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.